GlassScriptPhysician profile
Andrea Giomi
NPI 1265729461
$2,751.22
in general payments reported to CMS, 2019-2025
31 companies · $702 in 2025
The $702 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,440 · 2020: $289 · 2024: $321 · 2025: $702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,022.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $286.15 | 2019-2020 | |
| Pfizer INC. | $271.50 | 2019-2025 | |
| Amgen INC. | $256.88 | 2019-2025 | Evenity, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $237.75 | 2019-2025 | Airsupra |
| Novo Nordisk INC | $199.98 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $147.71 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $135.89 | 2020-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $131.52 | 2019-2025 | Veozah |
| Abbvie INC. | $124.08 | 2025 | |
| Amarin Pharma, INC. | $99.59 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $96.99 | 2019-2025 | |
| Abbott Laboratories | $81.97 | 2019-2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $80.62 | 2019-2024 | Eliquis |
| Allergan, INC. | $74.24 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $68.78 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $66.09 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Takeda Pharmaceuticals U.S.A., INC. | $50.27 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.93 | 2019 | |
| Radius Health, INC. | $42.30 | 2019-2020 | |
| Axsome Therapeutics, INC. | $38.86 | 2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $32.01 | 2019 | |
| Paratek Pharmaceuticals, INC. | $30.92 | 2024-2025 | Nuzyra, Xhance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.28 | 2025 | Xifaxan |
| Dynavax Technologies Corporation | $19.11 | 2025 | Heplisav-B |
| Cvrx, INC. | $18.13 | 2025 | Barostim Neo System |
| Antares Pharma, INC. | $17.84 | 2020 | |
| Esperion Therapeutics, INC. | $14.69 | 2025 | Nexletol |
| Exact Sciences Corporation | $14.34 | 2024 | Cologuard Collection Kit |
| Shire North American Group INC | $12.13 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.47 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Giomi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.